[1]
|
曹毛毛, 陈万青. GLOBOCAN 2020全球癌症统计数据解读[J]. 中国医学前沿杂志(电子版), 2021, 13(3): 63-69.
|
[2]
|
Poulsen, L.Ø., Qvortrup, C., Pfeiffer, P., Yilmaz, M., Falkmer, U. and Sorbye, H. (2015) Review on Adju-vant Chemotherapy for Rectal Cancer—Why Do Treatment Guidelines Differ so Much? Acta Oncologica, 54, 437-446.
https://doi.org/10.3109/0284186X.2014.993768
|
[3]
|
欧阳淦露. 全程新辅助治疗在高危局部晚期直肠癌患者中的疗效和安全性分析[J]. 中华胃肠外科杂志, 2019, 22(4): 349-359. https://doi.org/10.3760/cma.j.issn.1671-0274.2019.04.007
|
[4]
|
Fernández-Martos, C., Pericay, C., Aparicio, J., et al. (2010) Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecit-abine Plus Oxaliplatin (CAPOX) Compared with Induction CAPOX Followed by Concomitant Chemoradio-Therapy and Surgery in Magnetic Resonance Imaging Defined, Locally Advanced Rectal Cancer: Grupo Cancer de Recto 3 Study. Journal of Clinical Oncology, 28, 859-865.
https://doi.org/10.1200/JCO.2009.25.8541
|
[5]
|
Fernández-Martos, C., Garcia-Albeniz, X., Pericay, C., et al. (2015) Chemoradiation, Surgery and Adjuvant Chemotherapy Versus Induction Chemotherapy Followed by Chemoradi-ation and Surgery: Long-Term, Results of the Spanish GCR-3 Phase II Randomized Trial. Annals of Oncology, 26, 1722-1728. https://doi.org/10.1093/annonc/mdv223
|
[6]
|
Reibetanz, J. and Germer, C.T. (2015) Intensivierte adju-vante Chemotherapie mit FOLFOX beim multimodal behandelten Rektumkarzinom [Intensified Adjuvant Chemotherapy with FOLFOX in the Multimodal Treatment of Rectal Cancer]. Der Chirurg, 86, 79. https://doi.org/10.1007/s00104-014-2977-6
|
[7]
|
Ludmir, E.B., Palta, M., Willett, C.G., et al. (2017) Total Neoad-juvant Therapy for Rectal Cancer: An Emerging Option. Cancer, 123, 1497-1506. https://doi.org/10.1002/cncr.30600
|
[8]
|
NCCN (2022) National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 1, NCCN.
|
[9]
|
龙飞, 胡桂, 马敏, 等. 2021.V1版NCCN临床实践指南: 结肠癌/直肠癌更新解读(外科部分) [J]. 临床外科杂志, 2021, 29(5): 401-404.
|
[10]
|
梁小波. 2016版中国局部进展期直肠癌诊疗专家共识解读[J]. 临床外科, 2017, 25(4): 248-250.
|
[11]
|
Kim, H.S. and Kim, N.K. (2020) Challenges and Shifting Treatment Strategies in the Surgical Treatment of Locally Advanced Rectal Cancer. Annals of Gastroenterological Surgery, 4, 379-385. https://doi.org/10.1002/ags3.12349
|
[12]
|
Erlandsson, J., Holm, T., Pet-tersson, D., Berglund, Å., Cedermark, B., Radu, C., Johansson, H., Machado, M., Hjern, F., Hallböök, O., Syk, I., Glimelius, B. and Martling, A. (2017) Optimal Fractionation of Preoperative Radiotherapy and Timing to Surgery for Rectal Cancer (Stockholm III): A Multicentre, Randomised, Non-Blinded, Phase 3, Non-Inferiority trial. The Lancet Oncology, 18, 336-346. https://doi.org/10.1016/S1470-2045(17)30086-4
|
[13]
|
Kim, J.S., Jeong, S.Y., Shin, R., Oh, H.K., Park, K.J. and Park, J.G. (2012) Preoperative versus Postoperative Chemoradiotherapy for Locally Advanced Rec-tal Cancer. European Journal of Surgical Oncology, 38, 831.
https://doi.org/10.1016/j.ejso.2012.06.307
|
[14]
|
Sauer, R., Liersch, T., Merkel, S., et al. (2012) Preoperative ver-sus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial after a Median Follow-Up of 11 Years. Journal of Clinical Oncology, 30, 1926-1933. https://doi.org/10.1200/JCO.2011.40.1836
|
[15]
|
van Gijn, W., Marijnen, C.A., Nagtegaal, I.D., et al. (2011) Pre-operative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer: 12-Year Follow-Up of the Multicentre, Randomised Controlled TME Trial. The Lancet Oncology, 12, 575-582. https://doi.org/10.1016/S1470-2045(11)70097-3
|
[16]
|
Ogura, A., Konishi, T., Cunningham, C., et al. (2019) Neo-adjuvant (Chemo) Radiotherapy with Total Mesorectal Excision Only Is Not Sufficient to Prevent Lateral Local Recur-rence in Enlarged Nodes: Results of the Multicenter Lateral Node Study of Patients with Low cT3/4 Rectal Cancer. Journal of Clinical Oncology, 37, 33-43.
https://doi.org/10.1200/JCO.18.00032
|
[17]
|
Breugom, A.J., Swets, M., Bosset, J.F., et al. (2015) Adjuvant Chem-otherapy after Preoperative (chemo) Radiotherapy and Surgery for Patients with Rectal Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data. The Lancet Oncology, 16, 200-207. https://doi.org/10.1016/S1470-2045(14)71199-4
|
[18]
|
Hong, T.S. and Ryan, D.P. (2018) Total Neoadjuvant Ther-apy for Locally Advanced Rectal Cancer-The New Standard of Care? JAMA Oncology, 4, e180070. https://doi.org/10.1001/jamaoncol.2018.0070
|
[19]
|
Dossa, F., Chesney, T.R., Acuna, S.A. and Baxter, N.N. (2017) A Watch-and-Wait Approach for Locally Advanced Rectal Cancer after a Clinical Complete Response Following Neoad-juvant Chemoradiation: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 2, 501-513.
https://doi.org/10.1016/S2468-1253(17)30074-2
|
[20]
|
Bahadoer, R.R., Dijkstra, E.A., van Etten, B., et al. (2021) Short-Course Radiotherapy Followed by Chemotherapy before Total Mesorectal Excision (TME) versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial. [Published Correction Appears in Lancet Oncology, 2021 Feb, 22(2): e42]. The Lancet Oncology, 22, 29-42.
|
[21]
|
Schrag, D., Weiser, M., Saltz, L., et al. (2019) Challenges and Solutions in the Design and Execution of the PROSPECT Phase II/III Neoadjuvant Rectal Cancer Trial (NCCTG N1048/Alliance). Clinical Tri-als, 16, 165-175.
https://doi.org/10.1177/1740774518824539
|
[22]
|
Abdalla, A., Aref, A., Alame, A., et al. (2020) Does Response to Upfront FOLFOX Predict Eventual Clinical and Pathological Response after Completion of Total Neoadjuvanttherapy for Patients Diagnosed with Rectal Cancer? Observations from a Phase II Clinical Trial. Diseases of the Colon & Rectum, 63.
|
[23]
|
Cercek, A., Roxburgh, C.S.D., Strombom, P., et al. (2018) Adoption of Total Neoadjuvant Therapy for Local-ly Advanced Rectal Cancer. JAMA Oncology, 4, e180071. https://doi.org/10.1001/jamaoncol.2018.0071
|
[24]
|
Rouanet, P., Rullier, E., Lelong, B., et al. (2017) Tailored Treat-ment Strategy for Locally Advanced Rectal Carcinoma Based on the Tumor Response to Induction Chemotherapy: Pre-liminary Results of the French Phase II Multicenter GRECCAR4 trial. Diseases of the Colon & Rectum, 60, 653-663.
https://doi.org/10.1097/DCR.0000000000000849
|
[25]
|
Forastiere, A.A., Zhang, Q., Weber, R.S., Maor, M.H., Goepfert, H., Morrison, T.F.P., Glisson, B., Trotti, A., Ridge, J.A., Thorstad, W., Wagner, H., Ensley, J.F. and Cooper, J.S. (2013) Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients with Locally Advanced Larynx Cancer. Journal of Clinical Oncology, 31, 845-852. https://doi.org/10.1200/JCO.2012.43.6097
|
[26]
|
Benson, A.B., Venook, A.P., Al-Hawary, M.M., et al. (2018) Rectal Cancer, Version 2. 2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehen-sive Cancer Network, 16, 874-901.
https://doi.org/10.6004/jnccn.2018.0061
|
[27]
|
Fokas, E., Allgäuer, M., Polat, B., et al. (2019) Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapyfor Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. Journal of Clinical Oncology, 37, 3212-3222. https://doi.org/10.1200/JCO.19.00308
|
[28]
|
Fokas, E., Schlenska-Lange, A., Polat, B., Klautke, G., Grabenbauer, G.G., Fietkau, R., Kuhnt, T., Staib, L., Brunner, T., Grosu, A.L., Kirste, S., Jacobasch, L., Allgäuer, M., Flentje, M., Germer, C.T., Grützmann, R., Hildebrandt, G., Schwarzbach, M., Bechstein, W.O., Sülberg, H., Friede, T., Gaedcke, J., Ghadimi, M., Hofheinz, R.D., Rödel, C. and German Rectal Cancer Study Group (2022) Chemoradiotherapy Plus Induc-tion or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer: Long-Term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncology, 8, e215445. https://doi.org/10.1001/jamaoncol.2021.5445
|
[29]
|
Garcia-Aguilar, J., Patil, S., Gollub, M.J., et al. (2022) Organ Preservation in Patients with Rectal Adenocarcinoma Treated with Total Neoadjuvant Therapy. Journal of Clinical On-cology, 40, 2546-2556.
|
[30]
|
George, T.J., Yothers, G., Hong, T.S., Russell, M.M., You, Y.N., Parker, W., Jacobs, S.A., Lucas, P.C., Gollub, M.J., Hall, W.A., Kachnic, L.A., Vijayvergia, N. and Wolmark, N. (2019) NRG-GI002: A Phase II Clinical Trial Platform Using Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer (LARC)—First Experimental Arm (EA) Initial Results. Journal of Clinical Oncology, 37, Article 3505. https://doi.org/10.1200/JCO.2019.37.15_suppl.3505
|
[31]
|
Aref, A. and Abdalla, A. (2022) Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Induction or Consolidation Chemotherapy? Journal of Clinical Oncology, 40, 2515-2519. https://doi.org/10.1200/JCO.22.00506
|
[32]
|
Rahma, O.E., Yothers, G., Hong, T.S., et al. (2021) Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results from the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. JAMA Oncology, 7, 1225-1230. https://doi.org/10.1001/jamaoncol.2021.1683
|
[33]
|
Ciseł, B., Pietrzak, L., Michalski, W., et al., for the Polish Colo-rectal Study Group. (2019) Long-Course Preoperative Chemoradiation versus 5 × 5 Gy and Consolidation Chemotherapy for Clinical T4 and Fixed Clinical T3 Rectal Cancer: Long-Term Results of the Randomized Polish II Study. Annals of Oncology, 30, 1298-1303.
https://doi.org/10.1093/annonc/mdz186
|
[34]
|
Chatila, W.K., Kim, J.K., Walch, H., Marco, M.R., Chen, C.T., Wu, F., Omer, D.M., Khalil, D.N., Ganesh, K., Qu, X., Luthra, A., Choi, S.H., Ho, Y.J., Kundra, R., Groves, K.I., Chow, O.S., Cercek, A., Weiser, M.R., Widmar, M., Wei, I.H., Pappou, E.P., Nash, G.M., Paty, P.B., Shi, Q., Vakiani, E., Duygu, S.S., Donoghue, M.T.A., Solit, D.B., Berger, M.F., Shia, J., Pelossof, R., Romesser, P.B., Yaeger, R., Smith, J.J., Schultz, N., Sanchez-Vega, F. and Garcia-Aguilar, J. (2022) Genomic and transCriptomic Determinants of Response to Neoadjuvant Therapy in Rectal Cancer. Nature Medicine, 28, 1646-1655. https://doi.org/10.1038/s41591-022-01930-z
|
[35]
|
van der Valk, M.J.M., Hilling, D.E., Bastiaannet, E., et al. (2018) Long-Termoutcomes of Clinical Complete Responders after Neoadjuvanttreatment for Rectal Cancer in the Inter-national Watch & WaitDatabase (IWWD): An International Multicentre Registry Study. The Lancet, 391, 2537-2545. https://doi.org/10.1016/S0140-6736(18)31078-X
|
[36]
|
Smith, J.J., Strombom, P., Chow, O.S., et al. (2019) As-sessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients with a Completeresponse after Neoadjuvant Thera-py. JAMA Oncology, 5, e185896.
https://doi.org/10.1001/jamaoncol.2018.5896
|